Search | Clinical Trials Finder

Conditions: Pancreatic Neoplasm, Peutz-Jeghers Syndrome
Interventions: Biopsy, Fine Needle Aspiration (FNA), Secretin (human synthetic) - ChiRhoClin; Procedure · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Ovarian Cancer
Interventions: Genetic Counseling, Informed Consent Counseling; Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation, ATM Gene Mutation, PALB2 Gene Mutation
Interventions: Niraparib, Irinotecan; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer, HER2-negative Breast Cancer, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Deleterious PALB2 Gene Mutation
Interventions: Niraparib, Dostarlimab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 8
States / cities: New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CDK12 Gene Mutation, CHEK1 Gene Mutation, CHEK2 Gene Mutation, DNA Damage Response Gene Mutation, DNA Repair Gene Mutation, FANCA Gene Mutation, FANCD2 Gene Mutation, FANCL Gene Mutation, GEN1 Gene Mutation, NBN Gene Mutation, Prostate Carcinoma, RAD51 Gene Mutation, RAD51C Gene Mutation
Interventions: Niraparib, Niraparib Tosylate Monohydrate, Radical Prostatectomy; Drug · Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Chest Radiography, Computed Tomography, Magnetic Resonance Imaging, PSMA PET Scan, Surgical Procedure; Procedure · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Male only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 133
States / cities: Anchorage, Alaska • Phoenix, Arizona • Arroyo Grande, California + 96 more

Conditions: Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
Interventions: Secretin, MRI, Tumor marker gene test with CA19-9; Drug · Diagnostic Test · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 9,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2029
U.S. locations: 9
States / cities: New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more

Conditions: Pancreatic Cancer
Interventions: Mitomycin-C; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Ovarian Cancer, Genetic Predisposition
Interventions: Telephone Genetic Counseling, In-Person Genetic Counseling; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 25 Years to 74 Years · Female only
Enrollment: 1,012 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Prostatic Neoplasms
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 30 Years to 75 Years · Male only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2039
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Familial Ovarian Cancer, Familial Breast Cancer, BRCA1-associate Malignancies, BRCA2-associated Malignancies
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostatic Neoplasm, Prostate Cancer, BRCA2 Mutation, BRCA1 Mutation, ATM Gene Mutation, MMR Mutation, Lynch Syndrome, Genetic Predisposition to Disease
Interventions: Prostate cancer screening; Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 35 Years to 74 Years · Male only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2040
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atypical Ductal Breast Hyperplasia, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Interventions: curcumin, Biomarker analysis, Assessment of Dietary Intake, Daily Log; Dietary Supplement · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 19 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation
Interventions: Informational Intervention, Survey Administration; Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Metastatic Breast Cancer
Interventions: Placebo, Veliparib, Carboplatin, Temozolomide, Paclitaxel; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 34
States / cities: Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 24 more

Conditions: Solid Tumor
Interventions: Rucaparib; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 19
States / cities: Los Angeles, California • San Francisco, California • Fort Myers, Florida + 15 more

Conditions: BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, Estrogen Receptor Negative, HER2/Neu Negative, MLH1 Gene Mutation, MSH2 Gene Mutation, MSH6 Gene Mutation, PALB2 Gene Mutation, PMS2 Gene Mutation, Progesterone Receptor Negative, RAD51C Gene Mutation, RAD51D Gene Mutation, Triple-Negative Breast Carcinoma
Interventions: Educational Intervention, Genetic Counseling, Laboratory Biomarker Analysis, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 30 Years and older · Female only
Enrollment: 5,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 2
States / cities: Houston, Texas • Seattle, Washington

Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation, BRIP1 Gene Mutation, Ovarian Cancer
Interventions: Risk-reducing salpingectomy with delayed oophorectomy, Risk-reducing salpingo-oophorectomy; Procedure
Lead sponsor: University Medical Center Nijmegen; Other
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2040
U.S. locations: 11
States / cities: Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 6 more

Conditions: Body Mass Index 25 or Greater, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Breast Carcinoma, Cancer Survivor, Chronic Lymphocytic Leukemia, Fatigue, Health Status Unknown, Lynch Syndrome, Ovarian Carcinoma, Overweight
Interventions: Dietary Intervention, Internet-Based Intervention, Laboratory Biomarker Analysis, Questionnaire Administration, Telephone-Based Intervention; Dietary Supplement · Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 337 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neoplasms, Breast, Carcinoma of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Neoplasms
Interventions: niraparib, Physician's choice; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 25
States / cities: Tucson, Arizona • Los Angeles, California • Fort Myers, Florida + 20 more

Conditions: BRCA1 Mutation, POLD1 Gene Mutation, CDKN2A Mutation, BRCA2 Mutation, POLE Gene Mutation, APC Gene Mutation, ATM Gene Mutation, MLH1 Gene Mutation, BARD1 Gene Mutation, MSH2 Gene Mutation, BRIP1 Gene Mutation, MSH6 Gene Mutation, CHEK2 Gene Mutation, PMS2 Gene Mutation, PALB2 Gene Mutation, EPCAM Gene Mutation, RAD51C Gene Mutation, BMPR1A Gene Mutation, RAD51D Gene Mutation, SMAD4, PTEN Gene Mutation, GREM1
Interventions: Intervention Arm At-risk Relative/ARR Contacts, MyGene Portal, Standard of Care; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 25 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Uterine Serous Carcinoma, Recurrent Uterine Carcinosarcoma, Platinum Resistant Ovarian Cancer
Interventions: Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, Pharmacokinetic Study, Rucaparib Camsylate; Other · Biological · Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer
Interventions: Talazoparib Tosylate; Drug
Lead sponsor: Melinda Telli; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm, POLD1 Gene Mutation, POLE Gene Mutation, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Stage III Breast Cancer AJCC v7, Stage III Ovarian Cancer AJCC v8, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v8, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8
Interventions: Laboratory Biomarker Analysis, Pembrolizumab; Other · Biological
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 2
States / cities: New Brunswick, New Jersey • New York, New York

Search by objective public record fields.

Cancer of the Pancreas Screening Study (CAPS 3)

Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing

Combination Therapy in Cancers With Mutations in DNA Repair Genes

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

The Cancer of the Pancreas Screening-5 CAPS5)Study

Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene

Risk Education and Assessment for Cancer Heredity

Men at High Genetic Risk for Prostate Cancer

Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer

Prostate Cancer Genetic Risk Evaluation and Screening Study

Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer

Usefulness of Video-Based Intervention in Helping Participants Encourage Their Families to Get Tested for BRCA Gene Mutations

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability